Oxford Biomedica

Expanding Global Cell And Gene Therapies Will Drive Vector Opportunities

AnalystHighTarget

Not Invested

Consensus Narrative from 8 Analysts

Published

31 Aug 25

Updated

31 Aug 25

AnalystHighTarget's Fair Value

UK£8.71

35.0% undervalued

31 Aug

UK£5.66

73.1%

4.4%

73.1%

4.4%

Author's Valuation

UK£8.7

35.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

UK£8.7

35.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

18.32%

Biotech revenue growth rate

12.01%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.95%

Calculation

UK£45.10m

Earnings '28

25.05x

PE Ratio '28

UK£1.13b

Market Cap '28

UK£1.13b

Market Cap '28

105.96m

No. shares '28

UK£10.66

Share Price '28

UK£10.66 Share Price '28

Discounted to 2025 @ 6.95% p.a.

UK£8.71

Fair Value '25